NASDAQ:PNT POINT Biopharma Global (PNT) Stock Forecast, Price & News $9.41 +0.02 (+0.21%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$9.26▼$9.6550-Day Range$6.78▼$10.8652-Week Range$5.59▼$11.13Volume458,900 shsAverage Volume630,465 shsMarket Capitalization$994.45 millionP/E Ratio11.20Dividend YieldN/APrice Target$15.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media POINT Biopharma Global MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.0% Upside$15.71 Price TargetShort InterestBearish9.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.76) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector341st out of 1,010 stocksPharmaceutical Preparations Industry151st out of 494 stocks 3.5 Analyst's Opinion Consensus RatingPOINT Biopharma Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.71, POINT Biopharma Global has a forecasted upside of 67.0% from its current price of $9.41.Amount of Analyst CoveragePOINT Biopharma Global has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.85% of the float of POINT Biopharma Global has been sold short.Short Interest Ratio / Days to CoverPOINT Biopharma Global has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in POINT Biopharma Global has recently decreased by 1.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPOINT Biopharma Global does not currently pay a dividend.Dividend GrowthPOINT Biopharma Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PNT. Previous Next 2.7 News and Social Media Coverage News SentimentPOINT Biopharma Global has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for POINT Biopharma Global this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for PNT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added POINT Biopharma Global to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.Percentage Held by Insiders18.70% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.77% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for POINT Biopharma Global are expected to grow in the coming year, from ($0.76) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of POINT Biopharma Global is 11.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.94.Price to Earnings Ratio vs. SectorThe P/E ratio of POINT Biopharma Global is 11.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.12.Price to Book Value per Share RatioPOINT Biopharma Global has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About POINT Biopharma Global (NASDAQ:PNT) StockPOINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Stock News HeadlinesMay 25, 2023 | finance.yahoo.comPOINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCOMay 20, 2023 | americanbankingnews.comFY2023 EPS Estimates for POINT Biopharma Global Inc. (NASDAQ:PNT) Boosted by AnalystMay 29, 2023 | Behind the Markets (Ad)Why Your IRA Could Crash on June 16thChina will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.May 19, 2023 | seekingalpha.comPOINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong FinancialsMay 17, 2023 | americanbankingnews.comPOINT Biopharma Global Inc. Forecasted to Post Q1 2024 Earnings of ($0.29) Per Share (NASDAQ:PNT)May 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for POINT Biopharma Global Inc. (NASDAQ:PNT) Boosted by AnalystMay 17, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: POINT Biopharma Global (PNT), NewAmsterdam Pharma Company (NAMS)May 16, 2023 | msn.comOppenheimer Reiterates POINT Biopharma Global (PNT) Outperform RecommendationMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 15, 2023 | msn.comWhy Shares of Point Biopharma Global Rose MondayMay 15, 2023 | finance.yahoo.comPOINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 15, 2023 | finance.yahoo.comPOINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope ManufacturerMay 14, 2023 | investing.comPOINT Biopharma Global (PNT) Earnings Dates & ReportsMay 13, 2023 | americanbankingnews.comBrokerages Set POINT Biopharma Global Inc. (NASDAQ:PNT) Target Price at $16.25May 10, 2023 | finance.yahoo.comAre Investors Undervaluing POINT Biopharma Global Inc. (NASDAQ:PNT) By 46%?April 24, 2023 | marketwatch.comLantheus, POINT Biopharma Granted FDA Fast Track Designation for Lu-PNT2002 Prostate Cancer DrugApril 24, 2023 | finance.yahoo.comLantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate CancerApril 20, 2023 | finance.yahoo.comTaking A Look At POINT Biopharma Global Inc.'s (NASDAQ:PNT) ROEApril 18, 2023 | americanbankingnews.comAnalysts Set POINT Biopharma Global Inc. (NASDAQ:PNT) PT at $16.25April 12, 2023 | americanbankingnews.comPOINT Biopharma Global (NASDAQ:PNT) Shares Down 3.4% April 4, 2023 | finance.yahoo.comEckert & Ziegler to Supply POINT Biopharma with Actinium-225April 1, 2023 | americanbankingnews.comPOINT Biopharma Global Inc. Expected to Post Q1 2023 Earnings of ($0.35) Per Share (NASDAQ:PNT)April 1, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for POINT Biopharma Global Inc. Decreased by Analyst (NASDAQ:PNT)March 31, 2023 | americanbankingnews.comPOINT Biopharma Global (NASDAQ:PNT) Trading 6.6% Higher March 31, 2023 | americanbankingnews.comPOINT Biopharma Global Inc. Forecasted to Post FY2027 Earnings of $0.21 Per Share (NASDAQ:PNT)March 31, 2023 | americanbankingnews.comOppenheimer Comments on POINT Biopharma Global Inc.'s FY2027 Earnings (NASDAQ:PNT)March 30, 2023 | americanbankingnews.comWilliam Blair Weighs in on POINT Biopharma Global Inc.'s Q1 2023 Earnings (NASDAQ:PNT)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Company Calendar Last Earnings3/27/2023Today5/29/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.71 High Stock Price Forecast$22.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+67.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.84 Trailing P/E Ratio11.20 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net MarginsN/A Pretax Margin54.70% Return on Equity26.47% Return on Assets23.14% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.58 Sales & Book Value Annual Sales$226.58 million Price / Sales4.39 Cash Flow$0.94 per share Price / Cash Flow10.02 Book Value$4.68 per share Price / Book2.01Miscellaneous Outstanding Shares105,680,000Free Float85,920,000Market Cap$994.45 million OptionableNot Optionable Beta0.14 Key ExecutivesMr. Allan Charles Silber (Age 72)Exec. Chairman Comp: $677.8kDr. Joe A. McCann Ph.D. (Age 44)CEO & Director Comp: $740.31kDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $227.5kMs. Jessica D. Jensen M.P.H. (Age 41)MPH, Exec. VP of Clinical Devel. Comp: $541.59kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, Chief Financial Officer Ms. Justyna Kelly M.Sc. (Age 37)Chief Operating Officer Ms. Donna Husack B.A.VP of HRMr. Ari ShomairVP of Corp. Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Exec. VP of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Sr. VP of Bus. Devel.More ExecutivesKey CompetitorsCassava SciencesNASDAQ:SAVAMirum PharmaceuticalsNASDAQ:MIRMVerve TherapeuticsNASDAQ:VERVBiomea FusionNASDAQ:BMEAAvadel PharmaceuticalsNASDAQ:AVDLView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 57,004 shares on 5/18/2023Ownership: 0.065%New York State Common Retirement FundSold 12,906 shares on 5/18/2023Ownership: 0.037%Gluskin Sheff & Assoc Inc.Bought 10,000 shares on 5/16/2023Ownership: 0.731%Jane Street Group LLCBought 65,492 shares on 5/16/2023Ownership: 0.089%Alberta Investment Management CorpSold 5,326 shares on 5/16/2023Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions PNT Stock - Frequently Asked Questions Should I buy or sell POINT Biopharma Global stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PNT shares. View PNT analyst ratings or view top-rated stocks. What is POINT Biopharma Global's stock price forecast for 2023? 8 Wall Street analysts have issued 12-month price objectives for POINT Biopharma Global's stock. Their PNT share price forecasts range from $11.00 to $22.00. On average, they anticipate the company's stock price to reach $15.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts. How have PNT shares performed in 2023? POINT Biopharma Global's stock was trading at $7.29 at the beginning of 2023. Since then, PNT stock has increased by 29.1% and is now trading at $9.41. View the best growth stocks for 2023 here. When is POINT Biopharma Global's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our PNT earnings forecast. How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) issued its earnings results on Monday, March, 27th. The company reported $1.53 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $1.79. The company earned $226.58 million during the quarter, compared to the consensus estimate of $260 million. What ETFs hold POINT Biopharma Global's stock? ETFs with the largest weight of POINT Biopharma Global (NASDAQ:PNT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and iShares Micro-Cap ETF (IWC).Direxion Daily S&P Biotech Bull 3x Shares (LABU), What is POINT Biopharma Global's stock symbol? POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT." Who are POINT Biopharma Global's major shareholders? POINT Biopharma Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (10.00%), BlackRock Inc. (5.19%), Great Point Partners LLC (3.20%), State Street Corp (2.95%), Rubric Capital Management LP (2.50%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Allan C Silber, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin. View institutional ownership trends. How do I buy shares of POINT Biopharma Global? Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is POINT Biopharma Global's stock price today? One share of PNT stock can currently be purchased for approximately $9.41. How much money does POINT Biopharma Global make? POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $994.45 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.84 on an earnings per share basis. How can I contact POINT Biopharma Global? POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417. This page (NASDAQ:PNT) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.